SCHEMBL1193371

SCHEMBL1193371

Cc1nc(S)nc2nc[nH]c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 3/20 0.41
GDA Q9Y2T3 1/20 0.41
ADORA3 P0DMS8 4/20 0.40
ADORA1 P30542 4/20 0.40
MAP3K5 Q99683 1/20 0.40
XDH P47989 1/20 0.40
CDK2 P24941 6/20 0.39
DPP4 P27487 1/20 0.39
ALDH1A1 P00352 1/20 0.39
PNP P00491 1/20 0.38
CDK1 P06493 4/20 0.37
CCNB1 P14635 4/20 0.37
CCNA2 P20248 4/20 0.37
CCNA1 P78396 4/20 0.37
ADORA2A P29274 3/20 0.36
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
CHEK2 O96017 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Purine SCHEMBL27935141 0.83 ALDH1A1 (0.34) PDPK1GDAADORA3ADORA1MAP3K5
SCHEMBL9465644 0.80 GDA (0.41) PDPK1GDAADORA3ADORA1MAP3K5
SCHEMBL1275417 0.79 PDPK1 (0.44) PDPK1GDAADORA3ADORA1MAP3K5
SCHEMBL29366073 0.79 PDPK1 (0.44) PDPK1GDAADORA3ADORA1MAP3K5
Ammonia Solution, Strong SCHEMBL27800067 0.78 XDH (0.44) PDPK1GDAADORA3ADORA1MAP3K5
SCHEMBL94774 0.76 PDPK1 (0.66) PDPK1GDAMAP3K5XDHCDK2
SCHEMBL29421402 0.76 PDPK1 (0.66) PDPK1GDAMAP3K5XDHCDK2
SCHEMBL1724116 0.76 GDA (0.41) PDPK1GDAADORA3ADORA1MAP3K5
SCHEMBL4451634 0.76 XDH (0.61) PDPK1GDAADORA3ADORA1XDH
SCHEMBL320850 0.76 PDPK1 (0.66) PDPK1GDAMAP3K5CDK2DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117092260-A Liquid chromatography-mass spectrometry analysis method for simultaneously detecting 6 immunosuppressant concentrations 苏州和合医学检验有限公司 2023-11-21 CN claimed
CN-117074582-A Method for simultaneously detecting concentration of 6 immunosuppressants in blood 苏州和合医学检验有限公司 2023-11-17 CN claimed
CN-117074581-A Pretreatment method for blood sample for simultaneously detecting 6 immunosuppressant concentrations 苏州和合医学检验有限公司 2023-11-17 CN claimed
CN-104447746-A Compound for activating AMPK and application thereof HUAAN MEDICAL CO LTD 2015-03-25 CN claimed
CN-101856313-B Association of monosaccharides and adenosine and its cosmetic use OREAL 2014-02-19 CN claimed
CN-101856313-A Association of monosaccharides and adenosine and its cosmetic use OREAL 2010-10-13 CN claimed
US-20100029692-A1 METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS HOPITAL-SAINTE-JUSTINE (CA) 2010-02-04 US claimed
EP-1825254-A4 METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY PROMETHEUS LAB INC (US) 2009-01-14 EP claimed
US-7326694-B2 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders HOPITAL SAINTE-JUSTINE (CA) 2008-02-05 US claimed
EP-1825254-A2 METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY Prometheus Laboratories, Inc. (US) 2007-08-29 EP claimed
US-20050234078-A1 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders HOPITAL SAINTE-JUSTINE (CA) 2005-10-20 US claimed
US-20040097527-A1 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders HOPITAL SAINTE-JUSTINE 2004-05-20 US claimed
US-6680302-B2 ADMINISTERING A 6- MERCAPTOPURINE DRUG TO A PATIENT HAVING IMMUNE-MEDIATED GASTROINTESTINAL DISORDER AND DETERMINING A LEVEL OF 6-THIOGUANINE IN THE PATIENT HOSPITAL SAINTE-JUSTINE (CA) 2004-01-20 US claimed
CN-1431909-A Combinations for treating neoplasms YU BAOFA (US) 2003-07-23 CN claimed
US-20020082239-A1 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders HOPITAL-SAINTE-JUSTINE (CA) 2002-06-27 US claimed
US-6355623-B2 DETERMINING THE LEVEL OF 6-THIOGUANINE METABOLITE WHEREIN A LEVEL OF 6-THIOGUANINE LESS THAN ABOUT 230 PMOL PER 8 X 108 RED BLOOD CELLS INDICATES A DRUG INCREASE; A LEVEL OF 400PMOL INDICATES A DECREASE; NONTOXIC HOPITAL-SAINTE-JUSTINE (CA) 2002-03-12 US claimed
EP-1115403-A1 OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS Hospital Sainte-Justine (CA) 2001-07-18 EP claimed
US-20010006970-A1 Determining the level of 6-thioguanine metabolite wherein a level of 6-thioguanine less than about 230 pmol per 8 x 108 red blood cells indicates a drug increase; a level of 400pmol indicates a decrease; nontoxic HOPITAL SAINTE-JUSTINE 2001-07-05 US claimed
WO-2000016780-A1 OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS HOPITAL SAINTE-JUSTINE (CA) 2000-03-30 WO claimed
CN-1220605-A Nucleotide analogues for topical treatment of skin cell proliferative disorders KARL Y HOSTETLER (US) 1999-06-23 CN claimed